News

The partnership will use the HemoShear’s Reveal-Tx proprietary disease modeling platform, which applies principles of physiological blood flow to tissue derived from patients. The platform will help drug

Through the PRIME initiative, Ignyta will have enhanced EMA support, including optimizing the entrectinib development pathway, potentially accelerating assessment of the Marketing Authorisation Application (MAA), and engaging in

The FDA has granted Imfinzi priority review status. The US FDA sBLA submission acceptance is an important milestone for IMFINZI in a disease state where patients need better treatment

Impax Laboratories is a specialty pharmaceutical company, based in California while Amneal is a generic pharmaceutical manufacturer based in Bridgewater, New Jersey. Post merger, Amneal shareholders will own

Cabozantinib has achieved its primary endpoint of overall survival (OS) through demonstrating a statistically significant and clinically meaningful improvement in median OS compared to placebo in patients with

Further, side effects were generally manageable and primarily mild to moderate in severity. The results [Abstract #OA 05.06] were presented by Professor Benjamin Solomon, lead investigator and medical

The FDA also previously granted Breakthrough Therapy Designation for this application, which is the seventh indication for which Opdivo has received this designation. “Priority review of our sBLA

Allergan said that it will appeal against the ruling given by Judge William Bryson in the United States District Court for the Eastern District of Texas. The lawsuit

The data is being presented at the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Meeting in London, United Kingdom, by Christiane Querfeld,